Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
Giorgio V. Scagliotti, Rabab Mohamed Gaafar, Anna K. Nowak et al. · The Lancet Respiratory Medicine · 2019
Cited by 168 works. doi:10.1016/s2213-2600(19)30139-0
Authors
- Giorgio V. Scagliotti
- Rabab Mohamed Gaafar
- Anna K. Nowak
- Takashi Nakano
- Jan P. van Meerbeeck
- Sanjay Popat
- Nicholas J. Vogelzang
- Federica Grosso
- Rasha Aboelhassan
- Marko Jakopović
- Giovanni Luca Ceresoli
- Paul Taylor
- Francesco Orlandi
- Dean Anthony Fennell
- Silvia Novello
- Arnaud Scherpereel
- Kozo Kuribayashi
- S. Cedrés
- Jens Benn Sørensen
- Nick Pavlakis
References
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- Adaptive Sample Size Calculations in Group Sequential Trials
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
- Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma